Hubert Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA, USA.
Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA.
Hum Vaccin Immunother. 2023 Dec 31;19(1):2213603. doi: 10.1080/21645515.2023.2213603. Epub 2023 May 23.
The Advisory Committee on Immunization Practices (ACIP) has recommended human papillomavirus (HPV) vaccination for adolescents in the United States since 2006. Though recommended at a similar time to the routine recommendations for adolescent tetanus, diphtheria, and acellular pertussis vaccination (Tdap) and quadrivalent meningococcal vaccination (MCV4), HPV vaccine uptake has consistently lagged behind these other adolescent vaccines. The ACIP recommends HPV vaccination at 11-12 y, with vaccination starting at 9 y of age included as an option that is routinely encouraged by the American Academy of Pediatrics and American Cancer Society. To support efforts to increase HPV vaccination at the first opportunity, this commentary summarizes the current HPV vaccination recommendations and available evidence regarding HPV vaccination starting at 9 y - including recent studies and trials documenting the effectiveness of HPV vaccination at 9 in supporting vaccine series completion, while providing future directions for research and implementation to improve HPV vaccination.
自 2006 年以来，免疫实践咨询委员会（ACIP）一直建议美国为青少年接种人乳头瘤病毒（HPV）疫苗。尽管与青少年破伤风、白喉和无细胞百日咳疫苗（Tdap）和四价脑膜炎球菌疫苗（MCV4）的常规推荐时间相似，但 HPV 疫苗的接种率一直落后于其他青少年疫苗。ACIP 建议在 11-12 岁时接种 HPV 疫苗，从 9 岁开始接种作为一种选择，这一选择得到了美国儿科学会和美国癌症协会的常规鼓励。为了支持首次机会增加 HPV 疫苗接种的努力，本评论总结了目前的 HPV 疫苗接种建议和关于从 9 岁开始接种 HPV 疫苗的可用证据，包括最近的研究和试验，这些研究和试验记录了 9 岁时 HPV 疫苗接种在支持疫苗系列完成方面的有效性，同时为提高 HPV 疫苗接种提供了未来的研究和实施方向。
